John Maraganore, Jeremy Levin, Ron Cohen and Steven Holtzman

Biotech lead­ers ral­ly be­hind Chi­nese sci­en­tists in US, calls for 'mea­sured' poli­cies in wake of purges

A slate of biotech ex­ec­u­tives, ven­ture cap­i­tal­ists and aca­d­e­m­ic re­searchers have lent their voic­es to Chi­nese sci­en­tists work­ing in the US bio­med­ical field, am­pli­fy­ing con­cerns that re­cent sanc­tions could “cre­ate a cli­mate of fear and un­cer­tain­ty.”

The let­ter — draft­ed by Steven Holtz­man, Ron Co­hen, Je­re­my Levin and John Maraganore and signed by well over 100 in­dus­try fig­ures — cau­tions against vil­i­fy­ing or ex­clud­ing an eth­nic group at the ex­pense of the uni­ver­sal ef­fort to fight dis­ease. Levin cur­rent­ly chairs BIO, while Co­hen and Maraganore are past heads of the trade group.

High-pro­file ter­mi­na­tions of three Asian re­searchers at MD An­der­son in April first jolt­ed biotech lead­ers to­ward a re­al­iza­tion that their in­dus­try is not im­mune from na­tion­al vig­i­lance about over­seas in­flu­ence. Sub­se­quent con­tro­ver­sy at Emory in­volv­ing two promi­nent neu­ro­sci­en­tists of Chi­nese ori­gin fur­ther fu­elled wor­ries that re­searchers were be­ing pun­ished for con­duct­ing trans-Pa­cif­ic col­lab­o­ra­tive work that they were pre­vi­ous­ly en­cour­aged to do.

Feng “Franklin” Tao KU

Sig­nal­ing a tough crack­down against aca­d­e­m­ic es­pi­onage, the De­part­ment of Jus­tice has in­dict­ed a Uni­ver­si­ty of Kansas pro­fes­sor of fed­er­al fraud. Feng “Franklin” Tao, who works on sus­tain­able tech­nol­o­gy, was ac­cused of hid­ing his em­ploy­ment with a Chi­nese uni­ver­si­ty while con­duct­ing gov­ern­ment-fund­ed re­search in the US.

In their let­ter, Holtz­man, Co­hen, Levin and Maraganore (CEOs of Deci­bel, Acor­da, Ovid and Al­ny­lam, re­spec­tive­ly) em­pha­sized that they are for ac­tions against for­eign es­pi­onage and IP theft.

But ac­tions must not evolve in­to broad lim­i­ta­tions on col­lab­o­ra­tions be­tween Chi­nese and Amer­i­can sci­en­tists, as it would de­ter Chi­nese sci­en­tists from stay­ing in the US or even com­ing in the first place and thus be “dele­te­ri­ous to our na­tion­al in­ter­ests.”

Echo­ing opin­ions al­ready pub­lished by the ed­i­tors of Na­ture, Na­ture Biotech­nol­o­gy and for­mer NIH di­rec­tor (and ex-Sanofi R&D chief) Elias Zer­houni, they added:

(We) ad­vo­cate for mea­sured poli­cies that will both pro­tect U.S. in­tel­lec­tu­al prop­er­ty and con­tin­ue to fos­ter the di­ver­si­ty and col­lab­o­ra­tion that fu­el our abil­i­ty to ad­vance sci­ence and cure dis­ease. At a min­i­mum, uni­ver­si­ties must ef­fec­tive­ly com­mu­ni­cate and con­sis­tent­ly ap­ply their rules gov­ern­ing sci­en­tif­ic col­lab­o­ra­tions and IP oblig­a­tions, and they, as well as gov­ern­ment agen­cies, must clear­ly jus­ti­fy their ac­tions when they ac­cuse sci­en­tists of malfea­sance or seek to dis­miss them from their po­si­tions.

Last month, Zer­houni point­ed out in his op-ed that US pol­i­cy­mak­ers had ad­vo­cat­ed for sci­en­tif­ic ex­changes with Chi­na for years and in­sti­tu­tions had tac­it­ly sup­port­ed their re­searchers’ in­volve­ment in Chi­na’s Thou­sand Tal­ents Pro­gram.

Elias Zer­houni Sanofi

“The ‘rules,’ now pre­sent­ed and en­forced as se­vere vi­o­la­tions of U.S. ethics and in­tel­lec­tu­al prop­er­ty reg­u­la­tions, were not rig­or­ous­ly im­ple­ment­ed by of­fi­cials at many U.S. in­sti­tu­tions,” he wrote. “The con­ster­na­tion, sense of tar­get­ed dis­crim­i­na­tion, and fear in the Chi­nese-Amer­i­can sci­en­tif­ic com­mu­ni­ty are thus un­der­stand­able.”

While a re­cent sur­vey of End­points read­ers sug­gests a lack of con­sen­sus on the threat that Chi­nese-Amer­i­can sci­en­tif­ic com­mu­ni­ty faces, key play­ers are ap­par­ent­ly ea­ger to speak up be­fore the brain drain hap­pens in earnest.

Check out the full list of sig­na­to­ries here.

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

Almost two years after first buying into Genor Biopharma’s pipeline of cancer and autoimmune therapies, Hillhouse Capital has led a $160 million cash injection to push the late-stage assets over the finish line while continuing to fund both internal R&D and dealmaking.

The Series B has landed right around the time Genor would have listed on the Hong Kong stock exchange, according to plans reported by Bloomberg late last year. Insiders had said that the company was looking to raise about $200 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Fangliang Zhang (Imaginechina via AP Images)

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Almost exactly three years after Shanghai-based Legend came out of nowhere to steal the show at ASCO with jaw-dropping data on their BCMA-targeted CAR-T for multiple myeloma, the little player with Big Pharma connections is taking a giant step toward making it big on Wall Street. And this time they want to seal the deal on a global rep after staking out a unicorn valuation in what’s turned out to be a bull market for biotech IPOs — in the middle of a pandemic.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ken Frazier, AP Images

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

Nicholas Kartsonis had been running clinical infectious disease research at Merck for almost 2 years when, in mid-January, he got a new assignment: searching the pharma giant’s vast libraries for something that could treat the novel coronavirus.

The outbreak was barely two weeks old when Kartsonis and a few dozen others got to work, first in small teams and then in a larger task force that sucked in more and more parts of the sprawling company as Covid-19 infected more and more of the globe. By late February, the group began formally searching for vaccine and antiviral candidates to license. Still, while other companies jumped out to announce their programs and, eventually and sometimes controversially, early glimpses at human data, Merck remained silent. They made only a brief announcement about a data collection partnership in April and mentioned vaguely a vaccine and antiviral search in their April 28 earnings call.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Mark Genovese (Stanford via Twitter)

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

With an FDA OK for the use of filgotinib in rheumatoid arthritis expected to drop any day now, Gilead has recruited a new leader from academia to lead its foray into inflammatory diseases.

Mark Genovese — a longtime Stanford professor and most recently the clinical chief in the division of immunology and rheumatology — was the principal investigator in FINCH 2, one of three studies that supported Gilead’s NDA filing. In his new role as SVP, inflammation, he will oversee the clinical development of the entire portfolio.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Stephen Isaacs, Aduro president and CEO (Aduro)

Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the shell to new own­ers

After a drumbeat of failure, setbacks and reorganizations over the last few years, Aduro CEO Stephen Isaacs is handing over his largely gutted-out shell of a public company to another biotech company and putting up some questionable assets in a going-out-of-business sale.

Isaacs —who forged a string of high-profile Big Pharma deals along the way — has wrapped a 13-year run at the biotech with one program for kidney disease going to the new owners at Chinook Therapeutics. A host of once-heralded assets like their STING agonist program partnered with Novartis (which dumped their work on ADU-S100 after looking over weak clinical results), the Lilly-allied cGAS-STING inhibitor program and the anti-CD27 program out-licensed to Merck will all be posted for auction under a strategic review process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.

Federico Mingozzi (Spark)

Spark touts an­i­mal da­ta for a so­lu­tion to AAV gene ther­a­py's an­ti­body prob­lem

Among all the limitations of using an adeno-associated virus as a vector to deliver a gene — still the most established modality in gene therapy given years of trial and error and finally success — the presence of neutralizing antibodies, whether pre-existing or induced, looms large.

“When I think about the immune responses in AAV, I try to sort of layer them,” Federico Mingozzi, the CSO at Spark Therapeutics, told Endpoints News. “The antibody is the first layer. It’s the first block that you find when you’re trying to do gene transfer.”

Gilead re­leas­es an­oth­er round of murky remde­sivir re­sults

A month after the NIH declared the first trial on remdesivir in Covid-19 a success, Gilead is out with new results on their antiviral. But although the study met one of its primary endpoints, the data are likely to only add to a growing debate over how effective the drug actually is.

In a Phase III trial, patients given a 5-day dose of remdesivir were 65% more likely to show “clinical improvement” compared to an arm given standard-of-care. The trial, though, gave little indication for whether the drug had an impact on key endpoints such as survival or time-to-recovery. And in a surprising twist, a 10-day dosing arm of remdesivir didn’t lead to a statistically significant improvement over standard of care.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.